GIOTAG: A REAL-WORLD STUDY OF AFATINIB FOLLOWED BY OSIMERTINIB[1]

SEQUENTIAL THERAPY IN EVERYDAY CLINICAL PRACTICE

Real-world data on the sustained clinical benefit observed with the treatment sequence of first-line afatinib* followed by osimertinib

A global, observational study based on existing medical records of 204 patients with *EGFR* mutation-positive advanced NSCLC who were treated with first-line afatinib, developed the T790M mutation and were then treated with second-line osimertinib

Patients with *EGFR* mutation-positive advanced NSCLC (Del19, L858R) → First-line treatment with afatinib → Acquisition of T790M → Second-line treatment with osimertinib

Data were collected from existing medical records from Q4 2017 to Q2 2018

Reflecting the situation in clinical practice, the **everyday patient population** included patients with an ECOG PS ≥2 (15% of patients in this study)

Primary outcome measure: patients benefitted from prolonged targeted therapy with afatinib and osimertinib for almost 28 months before the need for chemotherapy**



79% of patients in the GioTag study were alive after 2 years; 84% of patients with an ECOG PS of 0 or 1 were alive at this timepoint



The median time on targeted therapies was longer in **Asian patients (46.7 months; 25% of patients)** and patients with **Del19 mutations (30.3 months; 74% of patients)**

Clinical benefit of this treatment sequence was observed across patient subgroups, including those with ECOG PS ≥2 or stable brain metastases

Additional observations: afatinib was **effective in controlling CNS progression** and **maintaining ECOG PS**

- Of patients with no brain metastases at baseline, 6.6% developed brain metastases during afatinib treatment. Of 21 patients with brain metastases when starting afatinib, 38% had no brain metastases when they began osimertinib
- 75% of patients maintained or even improved ECOG PS during afatinib treatment

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®. Registration conditions differ internationally; please refer to locally approved prescribing information; **Median follow-up time was 28.2 months.

CI, confidence interval; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer.

1. Hochmair MJ, et al. Future Oncol 2018 Oct 19. doi: 10.2217/fon-2018-0711. [Epub ahead of print].

ClinicalTrials.gov NCT number: NCT03370770.

European Union Summary of Product Characteristics (https://www.inoncology.com/sites/default/files/emea-combined-afatinib_SmPC_EU_Approval.pdf).

This information is from an international website that is intended for healthcare professionals not located in the United States of America (US) and the United Kingdom (UK). Afatinib is subject to country-specific regulations and the approved product label may vary from country to country. Information on this website is derived from the approved European Summary of Product Characteristics. Please refer to your local product label for full details.
Copyright © 2018 Boehringer Ingelheim International GmbH. This document and its contents are property of Boehringer Ingelheim (third-party sources are indicated) and are, inter alia, protected by copyright law. Complete or partial passing on to third parties, as well as copying, reproduction, publication or any other use by third parties, is not permitted.
All rights are reserved. November 2018. Vault ID: SC-CRP-02610

LET'S COLLABORATE
ONCOLOGY FROM BOEHRINGER INGELHEIM

Boehringer Ingelheim